Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Chronic Myeloid Leukemia (CML)

 

Dasatinib Versus Imatinib for Chronic Phase Chronic Myeloid Leukemia
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Investigator: Vivian G. Oehler, MD;   Conditions: Chronic Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01593254

Bosutinib versus Imatinib for Newly Diagnosed Chronic Myelogenous Leukemia (9210)
A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myelogenous Leukemia;    Status: Recruiting;   Study ID: NCT02130557

Bosutinib for Philadelphia Chromosome Positive CML Previously Treated with One or More Tyrosine Kinase Inhibitors (9238)
A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myeloid Leukemia (CML);    Status: Recruiting;   Study ID: NCT02228382